tldrdailynews.com logo
Tag

Glp 1 Drugs

All articles tagged with #glp 1 drugs

Body positivity endures as slimming trends rise with GLP-1 era
health13 days ago

Body positivity endures as slimming trends rise with GLP-1 era

A Axios piece argues the body positivity movement remains vital even as a GLP-1–driven slimming trend and celebrity focus dominate media, risking a return to thin-ideal norms. Experts warn this creates a two-tier world where access to medical weight interventions shapes self-perception and mental health, while activists emphasize reframing GLP-1s as disease-treating tools rather than vanity products. The fight for body diversity is framed as a social-justice issue that remains ongoing despite changing trends.

via Axios|
#body-image#body-positivity#glp-1-drugs
Heart protection from GLP-1 drugs fades quickly after stopping, study finds
health17 days ago

Heart protection from GLP-1 drugs fades quickly after stopping, study finds

A Washington University study of more than 333,000 U.S. veterans with type 2 diabetes found that continuous GLP-1 therapy reduced cardiovascular risk by about 18% after three years; stopping the medication for six months raised risk by 4%, after one year by 14%, and after two years by 22%, with restarting yielding only partial protection, highlighting the importance of long‑term use and accompanying lifestyle changes.

via AOL.com|
#bmj-medicine#cardiovascular-risk#glp-1-drugs
GLP-1 Weight-Loss Drugs Reveal Hidden Costs Beyond the Scale
health26 days ago

GLP-1 Weight-Loss Drugs Reveal Hidden Costs Beyond the Scale

A BuzzFeed Health feature examines how GLP-1 weight-loss medications (like Ozempic, Wegovy and Mounjaro) marketed for medical use are being used cosmetically, triggering a viral Reddit thread about a partner whose two-year Ozempic journey left her with a gaunt appearance, muscle loss, debt, and relationship strain. The piece highlights easy access via telehealth, aggressive marketing, and the risk of body dysmorphia or eating disorders when medical safeguards are bypassed. It emphasizes that these drugs are not miracle cures and should be paired with resistance training and adequate protein, while urging professional support for underlying psychological issues and broader societal pressures around body image.

via BuzzFeed|
#body-dysmorphia#glp-1-drugs#health
GLP-1 Medications Tied to Broad Decrease in Addiction Risk Among Veterans
health1 month ago

GLP-1 Medications Tied to Broad Decrease in Addiction Risk Among Veterans

A VA-led cohort study of 606,434 U.S. veterans with type 2 diabetes found that GLP-1 medicines (including Ozempic, Wegovy, Mounjaro, and Zepbound) are associated with a lower risk of developing substance use disorders across alcohol, opioids, nicotine, cocaine, cannabis and other substances—and with fewer hospitalizations, overdoses, and deaths among veterans who already have an addiction. The study also notes a 25% reduction in suicidal ideation. As observational research, it cannot prove causation, and results may reflect greater health engagement; randomized trials are underway, and GLP-1s are not yet approved as addiction treatments.

via Military.com|
#addiction#cohort-study#glp-1-drugs
GLP-1 Weight-Loss Drugs May Shield Heart Microvessels After Heart Attacks
science1 month ago

GLP-1 Weight-Loss Drugs May Shield Heart Microvessels After Heart Attacks

A Bristol/UCL study suggests GLP-1 weight-loss meds like semaglutide and liraglutide may protect heart tissue after a heart attack by relaxing pericytes and widening microvessels to prevent ‘no-reflow’—a finding from animal studies that hints at repurposing these drugs for post-infarct cardioprotection, though human trials are needed.

via SciTechDaily|
#glp-1-drugs#heart-attack#microvasculature
Obesity Persists in the U.S. While GLP-1 Weight-Loss Drugs Surge
medicine-and-health2 months ago

Obesity Persists in the U.S. While GLP-1 Weight-Loss Drugs Surge

A Pew Research Center analysis of 2024–2025 data finds about 40% of U.S. adults are obese (around 10% severely obese) with a slight decline since 2017–18; 65% say willpower alone isn’t enough to lose weight. Roughly half of Americans report hearing about Ozempic, Wegovy, and similar GLP-1 drugs extremely or very often, with women and older adults more likely to say so. Public opinion skews toward using GLP-1s for obesity-related health conditions rather than for weight loss alone. GLP-1 drugs have generated billions in revenue—Novo Nordisk’s 2024 GLP-1 sales totaled about $31.1 billion (majority from the U.S.), and Lilly’s Mounjaro/Zepbound have also surged. Medicaid coverage varies by state (13 cover GLP-1s for obesity, 7 cover some weight-loss drugs but not GLP-1s), and prescriptions rose from about 1.3 million in 2019 to 8.4 million in 2024, with spending climbing to roughly $8.6 billion.

via Pew Research Center|
#glp-1-drugs#medicaid-coverage#medicine-and-health
Real-world GLP-1 weight loss often endures after stopping therapy
health2 months ago

Real-world GLP-1 weight loss often endures after stopping therapy

A real-world analysis of 135,000+ patients on GLP-1 therapies (tirzepatide and semaglutide) found weight loss durability after discontinuation. Six months after stopping, about 28% of tirzepatide users regained weight, while 36% kept it off and 36% continued to lose; for semaglutide, ~33% regained, ~32% maintained, and ~35% still lost weight, with a median six‑month change of 0%. The findings suggest durability is possible in routine care and could support a disease-management approach, especially when paired with exercise counseling. Limitations include its observational nature and incomplete accounting for dose and lifestyle factors; results differ from some clinical trial findings and more research is needed to identify who maintains weight loss long-term.

via Reuters|
#drug-discontinuation#glp-1-drugs#health
Novo Nordisk's GLP-1 Weight-Loss Pills Spark Price Competition
business3 months ago

Novo Nordisk's GLP-1 Weight-Loss Pills Spark Price Competition

Novo Nordisk has announced a price reduction for its Wegovy weight-loss pill in the US to compete with Eli Lilly's market offerings, initiating a price war in the weight-loss drug industry. The company will offer lower doses at significantly reduced prices, aiming to attract more overweight and obese patients, especially following the recent FDA approval of an oral version of Wegovy. This move comes amid a competitive landscape with Lilly's upcoming drug, orforglipron, expected to be approved soon.

via Financial Times|
#business#glp-1-drugs#novo-nordisk
Top 3 Discounted Drug Stocks to Watch
business3 months ago

Top 3 Discounted Drug Stocks to Watch

The article discusses the recent developments in the GLP-1 drug market, highlighting Novo Nordisk's new pill and the potential of out-of-favor drug makers like Bristol Myers Squibb, Merck, and Pfizer as long-term investment opportunities due to their efforts to innovate and survive patent cliffs. Despite current setbacks, these companies are positioned for future growth, making them attractive for contrarian investors.

via The Motley Fool|
#business#glp-1-drugs#merck